Seoul National University Hospital: Leukemia trials
The registry lists 11 Leukemia studies with Seoul National University Hospital as lead sponsor. 2 are open to participants now and 1 have results posted.
Phase 1 4Phase 2 6Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell TransplantationRecruitingNCT06247501Phase 2
- Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic LeukemiaRecruitingNCT05210907Phase 1
- Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute LeukemiaCompletedNCT02440178Phase 2Results posted
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLStatus unknownNCT04842370Phase 1
- The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative NeoplasmStatus unknownNCT03558607Phase 1/2
- Efficacy and Safety of Nilotinib in CML-CPCompletedNCT03332511Phase 4
- Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.Status unknownNCT02047578Phase 2
- Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic LeukemiaCompletedNCT01556386
- Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell TransplantationStatus unknownNCT01472055Phase 2
- Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)CompletedNCT01247493Phase 2
- Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and AdolescentsStatus unknownNCT01239485Phase 1